Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by MARIA BOTTAZZI and JEROEN POLLET.
MARIA BOTTAZZI
Connection Strength
6.331
JEROEN POLLET
  1. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern. bioRxiv. 2022 Mar 22.
    View in: PubMed
    Score: 0.825
  2. SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. Hum Vaccin Immunother. 2021 08 03; 17(8):2356-2366.
    View in: PubMed
    Score: 0.773
  3. SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice. bioRxiv. 2021 Feb 09.
    View in: PubMed
    Score: 0.764
  4. A simple fluorescence-based assay for quantification of the Toll-Like Receptor agonist E6020 in vaccine formulations. Vaccine. 2017 03 07; 35(10):1410-1416.
    View in: PubMed
    Score: 0.579
  5. Immunopeptidomic MHC-I profiling and immunogenicity testing identifies Tcj2 as a new Chagas disease mRNA vaccine candidate. PLoS Pathog. 2024 Dec; 20(12):e1012764.
    View in: PubMed
    Score: 0.249
  6. Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins. Viruses. 2024 Sep 20; 16(9).
    View in: PubMed
    Score: 0.245
  7. A trivalent protein-based pan-Betacoronavirus vaccine elicits cross-neutralizing antibodies against a panel of coronavirus pseudoviruses. NPJ Vaccines. 2024 Jul 22; 9(1):132.
    View in: PubMed
    Score: 0.243
  8. A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2. Vaccines (Basel). 2023 Oct 01; 11(10).
    View in: PubMed
    Score: 0.229
  9. From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):495-500.
    View in: PubMed
    Score: 0.218
  10. Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate. Protein Expr Purif. 2022 02; 190:106003.
    View in: PubMed
    Score: 0.200
  11. Location and expression kinetics of Tc24 in different life stages of Trypanosoma cruzi. PLoS Negl Trop Dis. 2021 09; 15(9):e0009689.
    View in: PubMed
    Score: 0.199
  12. Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. Biochim Biophys Acta Gen Subj. 2021 06; 1865(6):129893.
    View in: PubMed
    Score: 0.192
  13. A method to probe protein structure from UV absorbance spectra. Anal Biochem. 2019 12 15; 587:113450.
    View in: PubMed
    Score: 0.173
  14. Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease. Infect Immun. 2018 04; 86(4).
    View in: PubMed
    Score: 0.156
  15. Characterization and Stability of Trypanosoma cruzi 24-C4 (Tc24-C4), a Candidate Antigen for a Therapeutic Vaccine Against Chagas Disease. J Pharm Sci. 2018 05; 107(5):1468-1473.
    View in: PubMed
    Score: 0.154
  16. Expression, purification, and characterization of the Necator americanus aspartic protease-1 (Na-APR-1 (M74)) antigen, a component of the bivalent human hookworm vaccine. Hum Vaccin Immunother. 2015; 11(6):1474-88.
    View in: PubMed
    Score: 0.125
  17. The zebrafish as a potential model for vaccine and adjuvant development. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):535-545.
    View in: PubMed
    Score: 0.060
  18. Harnessing RNA Technology to Advance Therapeutic Vaccine Antigens against Chagas Disease. ACS Appl Mater Interfaces. 2024 Apr 03; 16(13):15832-15846.
    View in: PubMed
    Score: 0.059
  19. Optimization and revision of the production process of the Necator americanus glutathione S-transferase 1 (Na-GST-1), the lead hookworm vaccine recombinant protein candidate. Hum Vaccin Immunother. 2014; 10(7):1914-25.
    View in: PubMed
    Score: 0.058
  20. The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2023 Nov; 17(11):e0011519.
    View in: PubMed
    Score: 0.058
  21. Localized cardiac small molecule trajectories and persistent chemical sequelae in experimental Chagas disease. Nat Commun. 2023 10 25; 14(1):6769.
    View in: PubMed
    Score: 0.058
  22. Heterologous mRNA-protein vaccination with Tc24 induces a robust cellular immune response against Trypanosoma cruzi, characterized by an increased level of polyfunctional CD8+ T-cells. Curr Res Immunol. 2023; 4:100066.
    View in: PubMed
    Score: 0.057
  23. The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection. bioRxiv. 2023 Jul 12.
    View in: PubMed
    Score: 0.056
  24. Vaccine-linked chemotherapy improves cardiac structure and function in a mouse model of chronic Chagas disease. Front Cell Infect Microbiol. 2023; 13:1106315.
    View in: PubMed
    Score: 0.055
  25. Localized cardiac metabolic trajectories and post-infectious metabolic sequelae in experimental Chagas disease. Res Sq. 2023 Jan 20.
    View in: PubMed
    Score: 0.055
  26. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci Immunol. 2021 07 15; 6(61).
    View in: PubMed
    Score: 0.049
  27. Vaccine-linked chemotherapy induces IL-17 production and reduces cardiac pathology during acute Trypanosoma cruzi infection. Sci Rep. 2021 02 05; 11(1):3222.
    View in: PubMed
    Score: 0.048
  28. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine. 2020 11 03; 38(47):7533-7541.
    View in: PubMed
    Score: 0.046
  29. TLR4 agonist protects against Trypanosoma cruzi acute lethal infection by decreasing cardiac parasite burdens. Parasite Immunol. 2020 10; 42(10):e12769.
    View in: PubMed
    Score: 0.046
  30. A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2019 05; 13(5):e0007413.
    View in: PubMed
    Score: 0.042
  31. Trichuris muris whey acidic protein induces type 2 protective immunity against whipworm. PLoS Pathog. 2018 08; 14(8):e1007273.
    View in: PubMed
    Score: 0.040
  32. Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine. 2018 03 27; 36(14):1853-1862.
    View in: PubMed
    Score: 0.039
  33. Identification, Characterization, and Structure of Tm16 from Trichuris muris. J Parasitol Res. 2017; 2017:4342789.
    View in: PubMed
    Score: 0.037
  34. Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate. J Pharm Sci. 2017 08; 106(8):1961-1970.
    View in: PubMed
    Score: 0.037
  35. Structure of SALO, a leishmaniasis vaccine candidate from the sand fly Lutzomyia longipalpis. PLoS Negl Trop Dis. 2017 03; 11(3):e0005374.
    View in: PubMed
    Score: 0.036
  36. Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease. Hum Vaccin Immunother. 2017 03 04; 13(3):621-633.
    View in: PubMed
    Score: 0.035
  37. Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic properties. Hum Vaccin Immunother. 2016 07 02; 12(7):1707-20.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.